ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Valeant Gets Medicis In Skin Drug Merger

by Ann M. Thayer
September 10, 2012 | APPEARED IN VOLUME 90, ISSUE 37

Valeant Pharmaceuticals has signed a $2.6 billion cash deal to acquire Medicis Pharmaceutical, based in Scottsdale, Ariz. The Canadian firm will pay $44.00 per share, or about one-third more than Medicis’ recent share price. Medicis sells prescription skin-enhancing and dermatology products. Valeant expects the combined company to have more than $1.7 billion in dermatology product sales this year. Valeant will operate its dermatology business under the Medicis name, with headquarters in Arizona and R&D in the U.S. and Canada.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment